Sökning: onr:"swepub:oai:DiVA.org:uu-360481" >
Changes in Weight A...
-
Weickert, Martin O.Univ Hosp Coventry, ENETS Ctr Excellence, ARDEN NET Ctr, Coventry CV2 2DX, W Midlands, England;Warwickshire Natl Hlth Serv Trust, Coventry CV2 2DX, W Midlands, England
(författare)
Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome
- Artikel/kapitelEngelska2018
Förlag, utgivningsår, omfång ...
-
ELSEVIER,2018
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-360481
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-360481URI
-
https://doi.org/10.1016/j.clinthera.2018.04.006DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Purpose: In the placebo-controlled Phase III TELE-STAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and >= 4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4.9] kg/m(2)) received placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg 3 times per day (TID) in addition to somatostatin analogue therapy. Weight loss is associated with uncontrolled carcinoid syndrome and may be associated with reduced survival.Methods: Assessment of the occurrence of weight change >= 3% at week 12 was prespecified in the statistical analysis plan.Findings: In 120 patients with weight data available, weight gain >= 3% was observed in 2 of 39 patients (5.1%) taking placebo [1.1), 7 of 41 (17.1%) taking telotristat ethyl 250 mg TID, and 13 of 40 (32.5%) taking telotristat ethyl 500 mg TID (P = 0.0017) at week 12. Weight loss >= 3% was observed in 5 of 39 patients (12.8%) taking placebo TID, 4 of 41 (9.8%) taking telotristat ethyl 250 mg TID, and 6 of 40 (15.0%) taking telotristat ethyl 500 mg TID (P = 0.77). Biochemical and metabolic parameters of serum albumin and cholesterol significantly increased (P = 0.02 and P = 0.001, respectively) in patients gaining weight and decreased in patients who lost weight, suggesting an improvement in overall nutritional status.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Kaltsas, GregoryUniv Hosp Coventry, ENETS Ctr Excellence, ARDEN NET Ctr, Coventry CV2 2DX, W Midlands, England;Warwickshire Natl Hlth Serv Trust, Coventry CV2 2DX, W Midlands, England
(författare)
-
Hörsch, DieterZent Klin Bad Berka, Bad Berka, Germany
(författare)
-
Lapuerta, PabloLexicon Pharmaceut Inc, The Woodlands, TX USA
(författare)
-
Pavel, MarianneFriedrich Alexander Univ Erlangen Nurnberg, Erlangen, Germany;Charite, Berlin, Germany
(författare)
-
Valle, Juan W.Univ Manchester, Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England
(författare)
-
Caplin, Martyn E.Royal Free Hosp, European Neuroendocrine Tumor Soc Ctr Excellence, Neuroendocrine Tumour Unit, London, England
(författare)
-
Bergsland, EmilyUniv Calif San Francisco, San Francisco, CA 94143 USA
(författare)
-
Kunz, Pamela L.Stanford Univ, Sch Med, Stanford, CA USA
(författare)
-
Anthony, Lowell B.Univ Kentucky, Lexington, KY USA
(författare)
-
Grande, EnriqueMD Anderson Int Canc Ctr, Madrid, Spain
(författare)
-
Öberg, Kjell,1946-Uppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob
(författare)
-
Welin, StaffanUppsala universitet,Onkologisk endokrinologi(Swepub:uu)stafweli
(författare)
-
Lombard-Bohas, CatherineHosp Civils Lyon, Hop Edouard Herriot, Lyon, France
(författare)
-
Ramage, John K.Kings Coll Hosp London, Kings Hlth Partners European Neuroendocrine Tumor, London, England
(författare)
-
Kittur, AshwinLexicon Pharmaceut Inc, The Woodlands, TX USA
(författare)
-
Yang, Qi M.Lexicon Pharmaceut Inc, The Woodlands, TX USA
(författare)
-
Kulke, Matthew H.Dana Farber Canc Inst, Boston, MA 02115 USA
(författare)
-
Univ Hosp Coventry, ENETS Ctr Excellence, ARDEN NET Ctr, Coventry CV2 2DX, W Midlands, England;Warwickshire Natl Hlth Serv Trust, Coventry CV2 2DX, W Midlands, EnglandZent Klin Bad Berka, Bad Berka, Germany
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Clinical Therapeutics: ELSEVIER40:6, s. 952-9620149-29181879-114X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Weickert, Martin ...
-
Kaltsas, Gregory
-
Hörsch, Dieter
-
Lapuerta, Pablo
-
Pavel, Marianne
-
Valle, Juan W.
-
visa fler...
-
Caplin, Martyn E ...
-
Bergsland, Emily
-
Kunz, Pamela L.
-
Anthony, Lowell ...
-
Grande, Enrique
-
Öberg, Kjell, 19 ...
-
Welin, Staffan
-
Lombard-Bohas, C ...
-
Ramage, John K.
-
Kittur, Ashwin
-
Yang, Qi M.
-
Kulke, Matthew H ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Clinical Therape ...
- Av lärosätet
-
Uppsala universitet